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Skin Graft Rejection Suppressed by Vaccination with T Cells 
In this issue, Mar&a Perez, Richard Edelson, Liliane Laroche, and 
Carole Berger of Yale University School of Medicine in New 
Haven, Connecticut, and Columbia University in New York City 
report the discovery of a new type of vaccination that may be useful 
for preventing unwanted immune responses, such as those causing 
the rejection of transplanted organs or autoimmune diseases. Perez, 
Edelson, and their colleagues have shown that they can take the T 
cells that mediate such an undesired immune attack, in this case the 
rejection of skin grafts by mice, and effectively turn the cells on 
themselves, so that they cause the immune system to suppress the 
responses that would otherwise destroy the skin grafts. The method 
may be applicable for treating autoimmune diseases, such as sys- 
temic lupus erythematosus, pemphigus vulgaris, and multiple scle- 
rosis, as well as for inhibiting the rejection of transplanted organs. 
The current study is an outgrowth of previous work in which 
Edelson and his colleagues devised a new therapy for cutaneous 
T-cell lymphoma. In this therapy, blood lymphocytes are first re- 
covered from the patients. These cells contain a high proportion of 
the T cells that are growing out of control and causing the lym- 
phoma. The lymphocytes are inactivated by exposing them to 8- 
methoxypsoralen (8-MOP) and ultraviolet light A (UVA) and re- 
turned to the patients. This treatment causes the lymphoma to 
regress, apparently by triggering an immune attack on the lym- 
phoma cells. “The T cells that have been so exposed (to 8-MOP and 
UVA irradiation) appear to induce an immune response against 
themselves and others like them,” Edelson says. 
Perez, Edelson, and their colleagues devised a mouse skin-graft 
model to test whether the T-cell therapy works in the way postu- 
lated. They prepared cells from the spleens of mice that were reject- 
ing a foreign skin graft. The spleen cells, which should be enriched 
in the T cells causing the rejection, were also inactivated by ex os- 
ing them to 8-MOP and UVA, and then injected into mice o P the 
same strain as the cell donors. These mice, when subsequently given 
skin grafts, proved to be tolerant to the foreign tissue, even though it 
was of the same genetic type as the grafts that originally elicited 
immune rejection. “All of these animals retained the grafts past 15 
days,” Perez says, “while all the controls rejected theirs in seven 
days.” 
In vitro assays of immune cell function in the mice that had 
received the treated spleen cells suggested that the animals were 
making immune cells that suppressed the graft rejection response. 
This is in accord with the Edelson group’s hypothesis about how the 
therapy for cutaneous T-cell lymphoma works. Lymphocytes that 
have been exposed to 8-MOP and UVA apparently elicit the pro- 
duction of suppressor cells that act in the one case against the lym- 
phoma T cells and in the other against the T cells that elicit skin 
graft rejection. 
Edelson notes that T-cell vaccinations comparable to those used 
for treating cutaneous T-cell lymphoma are beginning to be tested 
as therapies for a variety of autoimmune diseases that are thought to 
be caused by aberrant T-cell activities. The current study, he says, 
“doesn’t answer all the questions, but it demonstrates a scientific 
basis for the clinical responses being observed.” 
New Clues to How Ultraviolet Light Causes Tanning 
“Our goal in these studies is to try to understand how the signal 
from ultraviolet light is transduced into a chemical signal that re- 
sults in melanization,” says John Pawelek of Yale University School 
of Medicine in New Haven, Connecticut. The changes that lead to 
the tanning of skin had been thought to be a response to the cellular 
injury caused by ultraviolet light. But, Pawelek explains, those 
changes occur in such a highly reproducible manner-the same 
way every time for everybody -that tanning appears to be more 
closely regulated than it would be if it were only a generalized 
response to injury. 
In this issue, Pawelek and Jean Bolognia and Marilyn Murray, 
also of Yale, provide new evidence in support of the idea that mel- 
anization in response to ultraviolet B (UVB) irradiation is regulated 
in a specific fashion, through the activity of melanocyte stimulating 
hormone (MSH). The researchers have found that mouse mela- 
noma cells acquire an increased ability to bind MSH after they are 
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